HilleVax, Inc. (HLVX)
NASDAQ: HLVX · IEX Real-Time Price · USD
1.770
-0.090 (-4.84%)
Jul 19, 2024, 4:00 PM EDT - Market closed

Company Description

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States.

It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021.

HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

HilleVax, Inc.
HilleVax logo
Country United States
Founded 2020
IPO Date Apr 29, 2022
Industry Biotechnology
Sector Healthcare
Employees 90
CEO Dr. Robert M. Hershberg M.D., Ph.D.

Contact Details

Address:
321 Harrison Ave, Suite 500
Boston, Massachusetts 02118
United States
Phone (617) 213-5054
Website hillevax.com

Stock Details

Ticker Symbol HLVX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001888012
CUSIP Number 43157M102
ISIN Number US43157M1027
SIC Code 2836

Key Executives

Name Position
Dr. Robert M. Hershberg M.D., Ph.D. President, Chief Executive Officer and Chairman of the Board
Dr. Aditya Kohli Ph.D. Chief Business Officer and Director
Shane A. Maltbie Chief Financial Officer and Treasurer
Sean McLoughlin Chief Operating Officer
Dr. Anju Chatterji Ph.D. Chief Technology Officer
Paul S. Bavier J.D. General Counsel, Secretary and Chief Administrative Officer
Astrid Borkowski M.D., Ph.D. Chief Medical Officer
Ozzie Berger Senior Vice President of Regulatory Affairs

Latest SEC Filings

Date Type Title
Jul 8, 2024 8-K Current Report
Jun 10, 2024 8-K Current Report
May 31, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
May 9, 2024 EFFECT Notice of Effectiveness
May 9, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
Apr 26, 2024 ARS Filing
Apr 26, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 26, 2024 DEF 14A Other definitive proxy statements
Apr 12, 2024 PRE 14A Other preliminary proxy statements